Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut-liver crosstalk for clinical translation.

Combined alcohol and Western diet (DUAL model) synergistically exacerbated steatotic liver disease compared to Western diet alone.

• The DUAL model combined alcohol exposure with a high-fat, high-cholesterol (HFHC) Western diet in mice.
• The combined exposure produced more prominent steatohepatitis than WD feeding alone.
• Liver and gut phenotypes were evaluated via histochemistry, flow cytometry, gene expression, proteomic, and metabolomic analyses.
• Zebrafish larvae exposed to alcohol and HFHC diet were used as a validation model, confirming the synergistic effect.

DUAL-diet-induced disruption of the intestinal barrier led to LPS leakage into the bloodstream and subsequent TLR4-mediated hepatic inflammation.

• Intestinal barrier disruption was a key mechanism linking gut dysfunction to liver pathology in the DUAL model.
• LPS leakage into the bloodstream triggered TLR4-mediated inflammatory signaling in the liver.
• This pathway contributed to the prominent steatohepatitis observed in DUAL-fed mice.
• The mechanism was studied using primary human hepatocytes and HepG2 cells to investigate underlying processes.

Impaired intrahepatic lipid oxidation, particularly due to insufficient CPT-1 activity, contributed to steatohepatitis in the DUAL model.

• CPT-1 (carnitine palmitoyltransferase-1) activity was specifically identified as insufficient in DUAL-fed mice.
• The paper specifically highlights 'hepatocytic CPT-1c' as a key factor in the disrupted lipid metabolism.
• Enhanced intestinal fat absorption combined with impaired lipid oxidation contributed to fat accumulation in the liver.
• This represents a novel mechanistic finding described as unveiled 'for the first time' in the context of DUAL etiology SLD.

DUAL-induced gut microbiota changes in mice showed similarities to human dysbiosis in MASLD patients who consumed alcohol, including increases in Bacteroides and Alistipes.

• Gut microbiota effects were studied in both DUAL mice and MASLD patients with a history of alcohol consumption.
• Both the murine DUAL model and human MASLD patients with alcohol consumption showed an increase in Bacteroides and Alistipes.
• This translational similarity supports the DUAL mouse model as relevant to human disease.
• Multi-omics data analysis was used to characterize the dysbiosis.

Antibiotic-induced microbiota depletion (AIMD) improved pathology in DUAL-fed mice, indicating a causal role of the microbiota in the pathophysiology of DUAL steatohepatitis.

• AIMD was performed in DUAL-fed mice to test the causal contribution of gut microbiota to disease.
• Improvement in pathology following AIMD demonstrated that the microbiota plays a causal, not merely associative, role in steatohepatitis progression.
• This finding supports the microbiota-gut-liver axis as a key driver of SLD in the context of combined alcohol and metabolic risk factors.

Early microbiome modulation via fecal microbiota transplant (FMT) induced mild improvements in liver and gut physiology.

• FMT was performed as a microbiome modulation therapy in DUAL-fed mice.
• Probiotics were also tested as a microbiome modulation strategy alongside FMT.
• The improvements from FMT were described as 'mild,' suggesting early-stage intervention may have limited but measurable benefit.
• These findings underscore the potential of microbiome modulation as a novel therapeutic strategy for SLD.

Promoting abstinence from alcohol in addition to reducing metabolic burden is suggested as a useful clinical regime for patients with MASLD and MetALD.

• The study explicitly states that 'promoting abstinence in addition to reducing the metabolic burden could be a useful and recommended regime for patients with MASLD and MetALD.'
• This recommendation is based on findings showing that alcohol combined with metabolic factors causes 'profound aggravation of gut and liver damage.'
• The results have direct implications for clinical practice and policy regarding management of patients with steatotic liver disease of dual etiology.